Background

Hypertriglyceridemia (HTG) is associated with increased cardiovascular disease (CVD) risk. However, the cost burden of HTG-related CVD in high-risk US adults on statins has not been well characterized.

Objective

We estimated the HTG-related health care cost burden among US adults with CVD or diabetes taking statin therapy.

Methods

We estimated population sizes and annual health care costs among US adults aged ≥45 years with diabetes or CVD taking statin therapy with normal triglycerides (TGs) defined as TG < 150 mg/dL compared with those with HTG defined as TG ≥ 150 mg/dL. Population sizes were estimated from the 2007-2014 National Health and Nutrition Examination Surveys. Adjusted mean total annual health care costs in 2015 US dollars were estimated using the Optum Research Database. The annual total health care cost burden was estimated by multiplying the population size by the mean annual total incremental health care costs overall and within subgroups.

Results

There were 6.2 (95% confidence interval [CI], 5.4 - 7.1) million and 12.0 (95% CI, 11.1 – 12.9) million US adults aged ≥45 years with diabetes and/or CVD on statin therapy with TG ≥ 150 mg/dL and TG < 150 mg/dL, respectively. The mean adjusted incremental total one-year health care costs in adults with TG ≥ 150 mg/dL compared with those with TG < 150 mg/dL was $1730 (95% CI, $1160 - $2320). This leads to a projected annual incremental cost burden associated with HTG in patients with diabetes or CVD on statins of $10.7 billion (95% CI, $6.8 B - $14.6 B).

Conclusion

In US adults on statins and at high risk for CVD, the health care costs associated with HTG are substantial.

中文翻译：

---

他汀类药物治疗在患有糖尿病或动脉粥样硬化性心血管疾病的美国成年人中高甘油三酯血症的经济负担。

背景

高甘油三酸酯血症（HTG）与心血管疾病（CVD）风险增加相关。但是，尚未明确表征高危美国成年人中他汀类药物与HTG相关的CVD的费用负担。

客观的

我们估算了接受他汀类药物治疗的患有CVD或糖尿病的美国成年人中与HTG相关的医疗保健费用负担。

方法

我们估算了接受他汀类药物治疗的≥45岁糖尿病或CVD年龄≥45岁的美国成年人的人口规模和年度医疗保健费用，正常甘油三酸酯（TGs）定义为TG <150 mg / dL，而HTG定义为TG≥150 mg / dL 。人口规模是根据2007-2014年全国健康与营养检查调查估计的。使用Optum研究数据库估算了2015年调整后的平均年度医疗总费用。年度总医疗保健费用负担是通过将人口规模乘以总体上以及各亚组内的年度平均总增量医疗保健费用来估算的。

结果

年龄≥45岁且糖尿病和/或CVD接受他汀类药物治疗且TG≥150 mg /的美国成年人中有6.2（95％置信区间[CI]，5.4-7.1）百万和12.0（95％CI，11.1-12.9）百万美国成年人dL和TG <150 mg / dL。与TG <150 mg / dL的成年人相比，TG≥150 mg / dL的成年人的平均调整后的一年总医疗保健费用平均为$ 1730（95％CI，$ 1160-$ 2320）。这导致他汀类药物的糖尿病或CVD患者与HTG相关的预计年度增量成本负担为107亿美元（95％CI，$ 6.8 B-$ 14.6 B）。

结论

在使用他汀类药物且患有CVD的高风险的美国成年人中，与HTG相关的医疗保健费用相当可观。